Short-term administration of the ccr5 antagonist vicriviroc to patients with HIV and HCV coinfection is safe and tolerable

Journal of Acquired Immune Deficiency Syndromes

Volumn 53, Issue 1, 2010, Pages 78-85

  Fätkenheuer, Gerd ^a   Hoffmann, Christian ^b   Slim, Jihad ^c   Rouzier, Régine ^d   Keung, Anther ^e   Li, Jing ^e   Treitel, Michelle ^e   Sansone Parsons, Angela ^e   Kasserra, Claudia ^e   O'Mara, Edward ^e   Schürmann, Dirk ^e  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY OF KIEL   (Germany)

^c ST MICHAEL S MEDICAL CENTER   (United States)

^d Centre CAP   (France)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

CCR5 antagonist; HIV HCV coinfection; Vicriviroc

Indexed keywords

AMINOTRANSFERASE; PLACEBO; PROTEINASE INHIBITOR; RITONAVIR; VICRIVIROC; VIRUS RNA;

ABDOMINAL PAIN; ADD ON THERAPY; ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FLATULENCE; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LIVER DISEASE; MALE; MIXED INFECTION; NAUSEA; OTALGIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; RHINORRHEA; SHORT COURSE THERAPY; SINUSITIS; SORE THROAT; TREATMENT RESPONSE; VIRUS LOAD; VIRUS REPLICATION;

ADULT; ALPHA-FETOPROTEINS; ANTIGENS, CD; ANTIGENS, CD19; ANTIGENS, CD4; ANTIGENS, CD8; APYRASE; C-REACTIVE PROTEIN; CD4 LYMPHOCYTE COUNT; DOUBLE-BLIND METHOD; FEMALE; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOGLOBULINS; LIVER; LYMPHOCYTE SUBSETS; MALE; MIDDLE AGED; PIPERAZINES; PYRIMIDINES; RECEPTORS, CCR5; VIRAL LOAD;

EID: 74049091806     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181bb28dc     Document Type: Article

References (26)

1. Westby M, van der Ryst E. CCR5 antagonists: host-targeted antivirals for the treatment of HIV infection. Antivir Chem Chemother. 2005;16: 339-354.
2. Lederman MM, Penn-Nicholson A, Cho M, et al. Biology of CCR5 and its role in HIV infection and treatment. JAMA. 2006;296:815-826.
3. Gulick RM, Su Z, Flexner C, et al. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS Clinical Trials Group 5211. J Infect Dis. 2007;196: 304-312.
4. Zingman B, Suleiman J, DeJesus E, et al. Vicriviroc, a next generation CCR5 antagonist, exhibits potent, sustained suppression of viral replication in treatment-experienced adults: VICTOR-E1 48-week results. Presented at: 15th Conference on Retroviruses and Opportunistic Infections; February 2-5, 2008; Boston, MA. Abstract 39LB.
5. Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol. 2006;44:S6-S9.
6. + T-cell count in individuals coinfected with HIV-1. Blood. 2005;105:1170-1178.
7. Mohsen AH, Easterbrook PJ, Taylor C, et al. Impact of human immunodeficiency virus (HIV) infection on the progression of liver fibrosis in hepatitis C virus infected patients. Gut. 2003;52:1035-1040.
8. Shields PL, Morland CM, Salmon M, et al. Chemokine and chemokine receptor interactions provide a mechanism for selective T cell recruitment to specific liver compartments within hepatitis C-infected liver. J Immunol. 1999;163:6236-6243.
9. Kanto T, Hayashi N. Immunopathogenesis of hepatitis C virus infection: multifaceted strategies subverting innate and adaptive immunity. Intern Med. 2006;45:183-191.
10. + T cell-dendritic cell interaction. Nature. 2006;440:890-895.
11. Wheeler J, McHale M, Jackson V, et al. Assessing theoretical risk and benefit suggested by genetic association studies of CCR5: experience in a drug development programme for maraviroc. Antivir Ther. 2007;12: 233-245.
12. Woitas RP, Ahlenstiel G, Iwan A, et al. Frequency of the HIV-protective CC chemokine receptor 5-Delta32/Delta32 genotype is increased in hepatitis C. Gastroenterology. 2002;122:1721-1728.
13. Goulding C, McManus R, Murphy A, et al. The CCR5-delta32 mutation: impact on disease outcome in individuals with hepatitis C infection from a single source. Gut. 2005;54:1157-1161.
14. Gulick RM, Lalezari J, Goodrich J, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med. 2008;359:1429-1441.
15. Zingman B, Suleiman J, DeJesus E, et al. Vicriviroc in combination therapy with an optimized antiretroviral regimen for treatment-experienced subjects: the VICTOR-E1 trial. Presented at: 15th Conference on Retroviruses and Opportunistic Infections; February 3-6, 2008; Boston, MA. Abstract 795.
16. Stepanyuk O, Chiang TS, Dever LL, et al. Impact of adding maraviroc to antiretroviral regimens in patients with full viral suppression but impaired CD4 recovery. AIDS. 2009;23:1911-1913.
17. Cicconi P, Cozzi-Lepri A, Phillips A, et al. Is the increased risk of liver enzyme elevation in patients co-infected with HIV and hepatitis virus greater in those taking antiretroviral therapy? AIDS. 2007;21:599-606.
18. Sulkowski MS, Benhamou Y. Therapeutic issues in HIV/HCV-coinfected patients. J Viral Hepat. 2007;14:371-386.
19. Greaves W, Parker C, Suresh R, et al. Vicriviroc as a component of HAART in treatment-naïve individuals: final analysis of Study 3802. In: HIV DART 2006: Frontiers in Drug Development for Antiretroviral Therapies; December 10-14, 2006; Cancun, Mexico. Abstract 82.
20. Slim J, Diaz SR, DeJesus E, et al. Safety of vicriviroc in antiretroviral-experienced subjects: 12-week VICTOR-E1 results with updated 24-week data. Presented at: 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention; July 22-25, 2007, Sydney, Australia. Abstract WEPEA108.
21. Nichols WG, Steel HM, Bonny T, et al. Hepatotoxicity observed in clinical trials of aplaviroc (873140). Antimicrob Agents Chemother. 2008; 52:858-865.
22. Saltzman M, Rosenberg M, Kraan M, et al. Pharmacokinetics of SCH 417690 administered alone or in combination with ritonavir and efavirenz in healthy volunteers. Presented at: 6th International Workshop on Clinical Pharmacology of HIV Therapy; April 28-30, 2005; Quebec City, Canada. Abstract 6.5.
23. Sansone A, Keung A, Tetteh E, et al. Pharmacokinetics of vicriviroc are not affected in combination with five different protease inhibitors boosted by ritonavir. Presented at: 13th Conference on Retroviruses and Opportunistic Infections; February 5-9, 2006; Denver, CO. Abstract 582.
24. Schürmann D, Fätkenheuer G, Reynes J, et al. Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults. AIDS. 2007;21: 1293-1299.
25. Strizki JM, Tremblay C, Xu S, et al. Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2005;49:4911-4919.
26. Ramanathan R, Zhong R, Alvarez N, et al. Comparative metabolism and excretion of a novel CCR5 receptor antagonist, SCH 417690 (vicriviroc), in human, monkey and rat. Drug Metab Rev. 2005;37: 725-726.